American Society of Hirudotherapy

Brave new world: the current and future use of novel anticoagulants

Review published in Thrombosis Research (2008)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewDrug DevelopmentClinical LiteratureSpyropoulos AC · Thrombosis Research, 2008

Abstract

Advances in antithrombotic therapy began when traditional anticoagulant agents such as heparin and the vitamin K antagonists like Coumadin became commercially available in the 1940s and 1950s. Inherent limitations of these compounds, including the need for monitoring and multiple food and drug interactions (with coumadin), spurred the development of newer parenteral compounds like low molecular weight heparin, the pentasaccharide fondaparinux, and direct thrombin inhibitors such as hirudin, argatroban and bivalirudin with advantages over traditional compounds. Despite the failure of the first oral anticoagulant in 50 years--the direct thrombin inhibitor ximelagatran--due to issues with liver toxicity, new oral agents such as the Factor Xa inhibitors rivaroxaban, apixaban, YM-150, and DU-176b and oral direct thrombin inhibitors such as dabigatran are in advanced stages of development, with dabigatran and rivaroxaban now approved for use outside of the United States for thromboprophylaxis in the setting of orthopedic surgery. These and other novel agents have the potential to greatly expand our armamentarium to treat thromboembolic disease, with more targeted approaches to specific procoagulant complexes, a predictable anticoagulant response that does not require monitoring, and use in both acute and long-term treatment settings.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAdministration, OralAnticoagulantsAtrial FibrillationBenzimidazolesDabigatranDrug DiscoveryFactor Xa InhibitorsHumansMorpholinesOligosaccharidesPyrazolesPyridinesPyridonesRivaroxabanStrokeThiophenesVenous Thromboembolism

Summary

This review traces antithrombotic therapy from heparins and vitamin K antagonists through parenteral direct thrombin inhibitors (hirudin, argatroban, bivalirudin) to emerging oral agents, noting that ximelagatran failed due to liver toxicity while dabigatran and oral factor Xa inhibitors remain in advanced development.

Why This Matters for Hirudotherapy

This review traces the evolution of antithrombotic therapy from traditional agents (heparin, vitamin K antagonists) through newer parenteral and oral drugs, noting that inherent limitations of older compounds—monitoring requirements, food and drug interactions—drove development of alternatives. Hirudin is briefly listed alongside argatroban and bivalirudin as a parenteral direct thrombin inhibitor that offered advantages over traditional compounds; however, the review's primary focus is on emerging oral agents such as rivaroxaban, apixaban, and dabigatran. The relevance is limited to placing hirudin in historical context within the anticoagulant landscape. No original data, leech-therapy methodology, or secretome-specific findings are presented; hirudin is mentioned only in passing as a precursor class.

Citation

Reference (Vancouver style)

Spyropoulos AC. Brave new world: the current and future use of novel anticoagulants. Thromb Res. 2008;123 Suppl 1:S29-35. doi:10.1016/j.thromres.2008.08.010. PMID: 18835010

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.